These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 33745217)

  • 1. Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology.
    Chatelut E; Hendrikx JJMA; Martin J; Ciccolini J; Moes DJAR
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00757. PubMed ID: 33745217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Setting the Dose of Checkpoint Inhibitors: The Role of Clinical Pharmacology.
    Chatelut E; Le Louedec F; Milano G
    Clin Pharmacokinet; 2020 Mar; 59(3):287-296. PubMed ID: 31701469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
    Maritaz C; Broutin S; Chaput N; Marabelle A; Paci A
    J Hematol Oncol; 2022 Jan; 15(1):6. PubMed ID: 35033167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.
    Oude Munnink TH; Henstra MJ; Segerink LI; Movig KL; Brummelhuis-Visser P
    Clin Pharmacol Ther; 2016 Apr; 99(4):419-31. PubMed ID: 26265133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should Therapeutic Drug Monitoring for Monoclonal Antibodies Remain the Exception or Become the Norm?
    Stroh M; Lum BL
    Clin Pharmacol Ther; 2016 Sep; 100(3):215-7. PubMed ID: 26971373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
    Nehra J; Bradbury PA; Ellis PM; Laskin J; Kollmannsberger C; Hao D; Juergens RA; Goss G; Wheatley-Price P; Hotte SJ; Gelmon K; Tinker AV; Brown-Walker P; Gauthier I; Tu D; Song X; Khan A; Seymour L; Smoragiewicz M
    Invest New Drugs; 2020 Oct; 38(5):1442-1447. PubMed ID: 32020438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm?
    Strik AS; Wang YC; Ruff LE; Yashar W; Messmer BT; Mould DR
    AAPS J; 2018 Sep; 20(6):99. PubMed ID: 30187153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the efficacy and safety of immune checkpoint inhibitors by detecting the exposure-response: An inductive review.
    Cheng M; Zhang S; Liu J; Jiang S; Dong M
    Int Immunopharmacol; 2021 Aug; 97():107703. PubMed ID: 33933843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.
    Desnoyer A; Broutin S; Delahousse J; Maritaz C; Blondel L; Mir O; Chaput N; Paci A
    Eur J Cancer; 2020 Mar; 128():119-128. PubMed ID: 32037060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring in cancer--are we missing a trick?
    Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
    Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.
    Verheijen RB; Yu H; Schellens JHM; Beijnen JH; Steeghs N; Huitema ADR
    Clin Pharmacol Ther; 2017 Nov; 102(5):765-776. PubMed ID: 28699160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?
    Mir O; Broutin S; Desnoyer A; Delahousse J; Chaput N; Paci A
    Eur J Cancer; 2020 Mar; 128():103-106. PubMed ID: 32089494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
    Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
    Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
    Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S
    Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties.
    Imamura CK
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):14-18. PubMed ID: 30606646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology.
    Erku D; Schneider J; Scuffham P
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00862. PubMed ID: 34546005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
    Goldstein DA; Ratain MJ; Saltz LB
    JAMA Oncol; 2020 Nov; 6(11):1694-1695. PubMed ID: 32459313
    [No Abstract]   [Full Text] [Related]  

  • 19. Evidence for therapeutic drug monitoring of targeted anticancer therapies.
    Gao B; Yeap S; Clements A; Balakrishnar B; Wong M; Gurney H
    J Clin Oncol; 2012 Nov; 30(32):4017-25. PubMed ID: 22927532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors.
    Centanni M; Moes DJAR; Trocóniz IF; Ciccolini J; van Hasselt JGC
    Clin Pharmacokinet; 2019 Jul; 58(7):835-857. PubMed ID: 30815848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.